Allison Casey

Conference Coverage

Sacituzumab Govetican Shows Promise for Second-Line Extensive-Stage Small Cell Lung Cancer

09/05/2024

According to updated results from the TROPiCS-03 trial, sacituzumab govetican showed promising antitumor activity among patients with both platinum-resistant and platinum-sensitive extensive-stage small cell lung cancer in the second-line...

According to updated results...

09/05/2024

Oncology

News

Histotripsy Demonstrates Technical Success, Safety for Primary and Metastatic Liver Tumors

09/04/2024

Allison Casey ;

According to results from the parallel #HOPE4LIVER trials, the novel ablation technique of histotripsy met coprimary end points for technical success and safety among patients with primary and metastatic liver tumors.

According to results from the...

09/04/2024

IO Learning

News

Hearing Loss Among Pediatric Patients with Neurofibromatosis Type 1

08/29/2024

Allison Casey ;

According to a review of audiometric data, the rate of hearing loss among patients with neurofibromatosis type 1 (NF1) compared to the general population was higher than expected.

According to a review of...

08/29/2024

Oncology

News

No Difference in Survival Between Minimally Invasive and Open Staging Surgeries for Patients With Non-Endometrioid Endometrial Cancer

08/20/2024

Allison Casey ;

There were no differences found for progression-free survival, overall survival, or surgical complications between minimally invasive or open staging surgeries among patients with non-endometrioid endometrial cancer.

There were no differences found...

08/20/2024

Oncology

News

Impact of Social Support on Quality of Life For Patients With Endometrial Cancer

08/20/2024

Allison Casey ;

According to a prospective longitudinal study, the perceived presence of social support for patients with endometrial who underwent surgery was associated with better quality of life at 1 year post-surgery.

According to a prospective...

08/20/2024

Oncology

News

FDA Approved Lazertinib Plus Amivantamab for Advanced Non-Small Cell Lung Cancer With EGFR Mutations

08/20/2024

Allison Casey ;

The FDA has approved lazertinib plus amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.

The FDA has approved lazertinib...

08/20/2024

Oncology

News

Vemurafenib for Pediatric Patients With Tumors Harboring BRAF V600 Mutations

08/09/2024

Allison Casey ;

Though the phase 2 MATCH trial was terminated early due to poor accrual, vemurafenib did appear to be tolerable and a potential treatment option among pediatric patients with tumors harboring BRAF-V600 mutations.

Though the phase 2 MATCH trial...

08/09/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology